Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

25.4.2016: WILEX AG successfully completes capital increase. The Executive Management Board of WILEX AG today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 2,248,272 new shares. ...More




Seite gelesen: 484708 | Heute: 138